The Fort Washington, Pa., biotechnology company is selling 3 million shares of common stock through the offering, and expects to grant the underwriters a 30-day option to purchase up to an additional 450,000 shares. Vitae , which went public through a $55 million IPO last September, plans to use the bulk of the proceeds from the offering to continue the development of its most advanced new drug candidate: VTP-43742.